Womed, founded in Montpellier in 2018 by Gonzague Issenmann, Xavier Garric and gynaecologist Stéphanie Huberlant as a spin-off of the University of Montpellier, the CNRS and Nîmes University Hospital, develops biodegradable polymer films placed inside the uterus. Its first product, Womed Leaf, is inserted after surgery to remove intrauterine adhesions and keeps the uterine walls apart while they heal, according to the University of Montpellier. The EIC Accelerator granted €2,493,810 towards a total cost of €3,562,697 for the next step: turning the polymer into an intrauterine drug-delivery platform. The project ran from May 2024 to April 2026, according to CORDIS.
The project's report says Womed completed a pharmacokinetic study in sheep showing local delivery of mifepristone with minimal exposure elsewhere in the body, chose a European contract manufacturer and transferred its processes, and received positive scientific advice from a national medicines agency for its fibroid drug product, according to CORDIS. In 2026 Womed raised more than €7 million, €5 million from professional investors and €2.1 million through crowdfunding, to take its fibroid and uterine bleeding treatments into clinical trials, according to Baby VC. No human trial of the fibroid product has started yet.
Company file
- Legal entity
- Womed SAS, SIREN 837 961 978
- Founded
- February 2018, Montpellier
- President
- Gonzague Issenmann, co-founder
- Marketed product
- Womed Leaf, FDA-approved 2025
- Pipeline
- Fibroids, acute uterine bleeding, endometriosis
- US distribution
- KARL STORZ
- EIC funding
- Grant first, €2.49M
Where Womed Stands Now
In September 2025 the US Food and Drug Administration approved Womed Leaf as the first medical device for women with moderate to severe Asherman syndrome, based on the PREG2 randomised trial of 160 patients, according to BioSpace. The endoscopy group KARL STORZ distributes it in the US, according to Medical Product Outsourcing. Womed Leaf is sold in 14 European countries. Womed's accounts are not published in open data.
"The project aims to establish a new standard of care for uterine fibroids by enabling the safe, localized delivery of Selective Progesterone Receptor Modulators directly within the uterus."
Womed, EIC project reportThe Technology: A Film That Delivers a Drug
Uterine fibroids are usually treated with surgery or with drugs taken by mouth, which act on the whole body. Womed's approach loads a fibroid drug of the selective progesterone receptor modulator class into its intrauterine polymer, so it acts locally. The sheep study confirmed local action with minimal exposure elsewhere, according to the report. The same platform is meant to extend to endometriosis and uterine bleeding.
What the EIC Award Promised, and What the Record Shows
The project promised an intrauterine drug-delivery platform. It ended with the preclinical and manufacturing groundwork done and regulators' advice received. The first human study, the step that would show whether it works in women, still has to begin, now with private money.
- Animal pharmacokinetic studyDeliveredSheep study.
- Manufacturing transferDeliveredEU CDMO.
- Regulatory planValidatedScientific advice.
- First human trialNot startedPlanned.
The Money
Womed raised €6 million in 2024 to launch Womed Leaf and more than €7 million in 2026, including €2.1 million from crowdfunding, more than double its crowdfunding target. The EIC's grant-first award offered no equity that has been reported.
What Cannot Be Checked
Questions for the EIC
What the final project report says, which medicines agency gave scientific advice, when the fibroid trial will start, and what Womed Leaf sales amount to are not public.
Why Europe Should Care
Womed Leaf became the first FDA-approved barrier for Asherman patients, according to a US fertility surgeon quoted at its approval. Womed has already brought one European device to the US market. If its drug-delivery platform works, it would offer a local, non-surgical option for fibroids.
What the award promised
An intrauterine drug-delivery platform for fibroids and other conditions.
What the record shows
Preclinical work done, €7M raised, no human trial yet.
The Verdict
Groundwork laid
Womed used the EIC grant to prepare its second product and has a first product already approved. The clinical proof is still to come.
Womed and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
